Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis
- PMID: 33084216
- DOI: 10.1111/1754-9485.13114
Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis
Abstract
Introduction: We aimed to investigate the prognostic and clinical values of two volumetric PET pjmirometers used in conjunction with SUVmax at different thresholds in invasive ductal carcinoma (IDC).
Methods: A total of 139 metastatic IDC BC who underwent 18F-FDG PET/CT imaging were included to study. MTV and TLG (40%, 50%, 60% and 70%) used in conjunction with primary tumour SUVmax . Nodal involvement, distant metastasis, ER, PR, Ki-67 expression and survival data evaluated by comparing FDG PET pjmirometers.
Results: Mean ± SD SUVmax of lesions (n = 139) was 13.97 ± 9.21. Primary tumour 18F-FDG uptake associated increased tumour diameter (>2 cm), high Ki-67 (>15%) and distant organ metastasis (DOM) (P = 0.015, 0.005 and 0.016, respectively). There was significant association between molecular subtypes and SUVmax (P = 0.002). High MTV associated with tumour diameter (MTV 40-70%), axillary lymph node (ALN) diameter (MTV 40-70%), and distant nodal metastasis (DNM) (MTV 50-70%). High TLG associated with tumour diameter (TLG 40-70%), high Ki-67 (TLG 40-70%), ALN metastasis (TLG 40%), ALN diameter (TLG 40-70%) and DNM (TLG 40-70%). Median survival found shorter in DOM patients (P = 0.030, Log Rank = 0.110).
Conclusion: We think evaluation of MTV and TLG at different thresholds in addition to SUVmax would enhance diagnostic and prognostic value of 18F-FDG PET/CT, and thus contribute to disease management.
Keywords: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; breast cancer; metabolic tumour volume; total lesion glycolysis.
© 2020 The Royal Australian and New Zealand College of Radiologists.
References
-
- Yu F, Quan F, Xu J et al. Breast cancer prognosis signature: linking risk stratification to disease subtypes. Brief Bioinform. 2018; 3: 1-11.
-
- Arslan E, Çermik TF, Trabulus FD, Talu EC, Başaran Ş. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. Nucl Med Commun. 2018; 39(7): 680-90.
-
- Kang S, Kim EH, Hwang JE et al. Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. Biochem Biophys Res Comm. 2019; 511(1): 185-91.
-
- Chiacchio S, Evangelista L, Alsharif A et al. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma. Q J Nucl Med Mol Imaging. 2018; 62(1): 101-11.
-
- Chen W, Zhu L, Yu X, Fu Q, Xu W, Wang P. Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT. Diag Interv Radiol. 2018; 24(6): 336.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials